# Quentis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quentis-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.quentistx.com
- Total disclosed funding: $48M
- Latest round: Series A (Feb 27, 2018)
- Investors on record: 7

## About

Quentis Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Their advanced approaches leverage proprietary technology to target disease mechanisms effectively.Founded in 2016, Quentis Therapeutics, Inc. is headquartered in New York, US and specializes in cancer therapeutics. The company successfully raised USD 48.00 mn in Series A funding on February 27, 2018, with investment from firms like AbbVie Biotech Ventures and Polaris Partners. The firm has completed 1 deal to date.The company offers a range of innovative cancer therapies designed to meet specific medical needs, focusing primarily on targeted treatments. These products aim to enhance treatment efficacy and improve patient outcomes in oncology. Quentis Therapeutics serves a diverse client base that includes healthcare providers, research institutions, and pharmaceutical companies across North America and Europe. Since their initial product offerings, these therapies have gained traction in the market, reflecting the company's commitment to quality and innovation.Quentis Therapeutics generates revenue through a combination of strategic partnerships and direct contracts with healthcare providers, which include both research collaborations and clinical trial agreements. Their pricing strategy is designed to accommodate various healthcare systems, ensuring accessibility while supporting ongoing research and development efforts. This multifaceted revenue approach aims to foster long-term relationships with partners and clients in the oncology sector.Quentis Therapeutics plans to utilize the recent USD 48.00 mn raised in Series A funding to accelerate the development of new cancer therapies, with several products currently in preclinical stages targeting specific tumor types expected to be launched by 2023. The company also aims to expand its market presence in Europe and Asia by 2024, building on its existing partnerships to support this geographic expansion. Additionally, the funding will help enhance their research capabilities and facilitate collaborations with leading research institutions.

## Funding rounds

- Series A, Feb 27, 2018, $48M — Versant Ventures, Polaris Partners, Alexandria Venture Investments, Yonghua Capital, AbbVie Ventures, Taiho Pharmaceutical, New York Venture Partners

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- Taiho Pharmaceutical — Series A
- New York Venture Partners (https://capitalatlas.ai/funds/new-york-venture-partners) — Series A